Diligence memo · auto-generated · as of July 2, 2026
Aruka Bio, Inc.
Aruka Bio, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Aruka Bio, Inc. operates in Biotech / Pharma, based in PRINCETON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aruka Bio, Inc. has raised $3.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.5M on 2024-04-17.
Most recent recorded round closed around 2024-04-17.
Valuation (modeled)modeled
Provath models Aruka Bio, Inc. at approximately $19M (range $2.6M–$54M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.11× the median modeled value of Seed Biotech / Pharma companies in 2022–2024 (14 peers) — value vs value, same stage and era. Within the normal band (111% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.2 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 44% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 42% of those peers.
Closest niche peers: Outer Biosciences, LLC, Slate Bio, Inc., CASS Pharmaceuticals, Inc., FOOP Organic Biosciences, Inc., Trio Pharmaceuticals, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.